VI

VIVOZON PHARMACEUTICAL CO., LTD.

Develops multi-target drugs for pain and central nervous system (CNS) diseases.

082800 | KO

Overview

Corporate Details

ISIN(s):
KR7082800004
LEI:
Country:
South Korea
Address:
경기도 화성시 향남읍 제약공단2길 34-40, 화성시

Description

VIVOZON PHARMACEUTICAL CO., LTD. is a research and development company specializing in the discovery and commercialization of innovative drugs, with a primary focus on pain and central nervous system (CNS) diseases. The company utilizes a multi-target drug development platform to create new chemical entities that act on multiple targets to achieve synergistic efficacy. This approach integrates efficacy-based screening from the early stages of discovery to identify candidate substances with a high potential for successful clinical development. Its lead pipeline candidate is Opiranserin (VVZ-149), a first-in-class, non-narcotic injectable analgesic for post-operative pain management. The company is actively expanding its pipeline to address a broader range of unmet medical needs within the CNS field.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-12-23 00:00
주식등의대량보유상황보고서(일반)
Korean 99.5 KB
2024-12-23 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.5 KB
2024-12-17 00:00
주식등의대량보유상황보고서(일반)
Korean 93.9 KB
2024-12-16 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.2 KB
2024-12-12 00:00
증권발행결과(자율공시) (제21회차 CB)
Korean 6.0 KB
2024-12-12 00:00
투자판단관련주요경영사항 ('어나프라주(오피란제린염산염)' 식품의약품안전처 품목허가 승인)
Korean 8.4 KB
2024-12-06 00:00
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 58.5 KB
2024-12-02 00:00
주요사항보고서(전환사채권발행결정)
Korean 41.8 KB
2024-11-19 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 22.5 KB
2024-11-18 00:00
[기재정정]전환청구권행사 (제19회차)
Korean 11.5 KB
2024-11-14 00:00
분기보고서 (2024.09)
Korean 1.3 MB
2024-11-13 00:00
전환청구권행사 (제19회차)
Korean 8.5 KB
2024-08-14 00:00
반기보고서 (2024.06)
Korean 1.3 MB
2024-07-22 00:00
전환가액의조정 (제20회차)
Korean 15.9 KB
2024-06-20 00:00
전환가액의조정 (제20회차)
Korean 15.4 KB

Automate Your Workflow. Get a real-time feed of all VIVOZON PHARMACEUTICAL CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for VIVOZON PHARMACEUTICAL CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for VIVOZON PHARMACEUTICAL CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.